Compare GMRE & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMRE | NPCE |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.0M | 514.3M |
| IPO Year | N/A | 2021 |
| Metric | GMRE | NPCE |
|---|---|---|
| Price | $36.22 | $17.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $40.50 | $18.00 |
| AVG Volume (30 Days) | 95.8K | ★ 270.1K |
| Earning Date | 02-26-2026 | 03-03-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,829,000.00 | $94,864,000.00 |
| Revenue This Year | $7.49 | $24.82 |
| Revenue Next Year | $3.18 | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.04 | ★ 24.08 |
| 52 Week Low | $29.05 | $7.56 |
| 52 Week High | $45.75 | $18.98 |
| Indicator | GMRE | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 70.17 | 58.95 |
| Support Level | $34.79 | $15.68 |
| Resistance Level | $35.61 | $17.90 |
| Average True Range (ATR) | 0.69 | 0.94 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 93.16 | 69.78 |
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.